On May 15, 2026, Tonix Pharmaceuticals shared data from a Phase 1 trial for its Lyme disease product TNX-4800, predicting it will maintain effective serum levels for six months. The two-dose regimen aims for a primary endpoint of maintaining serum levels above the Minimum Effective Concentration of 10 µg/mL.